Welcome to our dedicated page for Scopus Biopharma news (Ticker: SCPS), a resource for investors and traders seeking the latest updates and insights on Scopus Biopharma stock.
Scopus Biopharma Inc. (SCPS) is an innovative biopharmaceutical company developing cutting-edge therapies for diseases with critical unmet needs. This dedicated news hub provides investors and industry professionals with essential updates on clinical trials, strategic partnerships, and therapeutic advancements.
Access timely information about SCPS's progress in immuno-oncology treatments, antiviral therapies, and regenerative medicine development. Our curated news collection features verified updates on trial milestones, research collaborations with leading institutions, and financial developments impacting the company's trajectory.
Key updates include progress reports on cancer treatment candidates, partnership announcements with academic research centers, and analyses of the company's financial position. Bookmark this page to stay informed about SCPS's contributions to biopharmaceutical innovation and their pursuit of transformative medical solutions.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced plans for an exchange offer allowing shareholders to exchange common stock for X Units. Each X Unit consists of one share of common stock and one new warrant, with no cash consideration required. Holders can tender all, some, or none of their stock, maintaining unmodified shares. The X Warrants will be exercisable at $9.00 per share starting January 2, 2023. Additionally, the company will seek Nasdaq listing for the X Units and Warrants, enhancing shareholder value and long-term investment incentives.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced a $9 million follow-on public offering of 1,000,000 shares at $9.00 per share. The underwriters have a 45-day option to purchase an additional 150,000 shares. This offering is expected to close on January 29, 2021, subject to customary conditions. Proceeds will primarily fund the development of Scopus's lead drug candidate, a targeted immuno-oncology gene therapy. The Benchmark Company, LLC is the Sole Bookrunning Manager for this offering.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the successful completion of clinical lot manufacturing, a crucial step towards its Phase 1 clinical trial for non-Hodgkin's lymphoma. This milestone will enable the finalization of the investigational new drug (IND) application to the FDA. The company is developing a unique immuno-oncology gene therapy to treat multiple cancers, aiming to combine its lead drug candidate with checkpoint inhibitors like Keytruda. The management expressed confidence in the potential of upcoming clinical updates to enhance shareholder value.
Scopus BioPharma (Nasdaq: SCPS) has announced the appointment of several new members to its Board of Directors as part of its recent IPO and listing on the Nasdaq Global Market. The newly appointed directors are Raphael Hofstein, Lesley Russell, David Battleman, David Buckel, and David Weild IV, all recognized leaders in biopharmaceutical and capital markets. Chairman Joshua R. Lamstein emphasized the significant industry experience these new directors bring, aiming to enhance the company's mission of advancing therapeutics for cancer treatment.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the closing of its initial public offering, successfully selling 575,000 shares at $5.50 each. The offering included shares from the exercised over-allotment option. Proceeds will primarily fund the development of a novel immuno-oncology gene therapy targeting various cancers. The offering statement was filed with the SEC on December 14, 2020. The transaction was managed by The Benchmark Company, LLC, with Joseph Gunnar & Co., LLC as co-manager.
FAQ
What is the current stock price of Scopus Biopharma (SCPS)?
What is the market cap of Scopus Biopharma (SCPS)?
